Table 4.
Perception on clinical trial participation barriers.
| Not important or not at all important 1 | Important or Very important 1 | p-value2 | ||
|---|---|---|---|---|
| Investigator |
The friendliness of the clinical and researchers | 42 (8.96%) | 427 (91.04%) | |
| Non-underrepresented | 28 (9.15%) | 278 (90.85%) | 0.839 | |
| Underrepresented | 14 (8.59%) | 149 (91.41%) | ||
| Being given the results of my trial after my participation had ended | 22 (4.74%) | 442 (95.26%) | ||
| Non-underrepresented | 10 (3.3%) | 293 (96.7%) | 0.045 | |
| Underrepresented |
12 (7.45%) |
149 (92.55%) |
||
| Study Protocol |
Whether I would be paid to participate | 202 (43.35%) | 264 (56.65%) | |
| Non-underrepresented | 147 (48.2%) | 158 (51.8%) | 0.004 | |
| Underrepresented | 55 (34.16%) | 106 (65.84%) | ||
| The possibility that I might be given a placebo (inactive treatment) | 138 (29.49%) | 330 (70.51%) | ||
| Non-underrepresented | 90 (29.51%) | 215 (70.49%) | 0.989 | |
| Underrepresented | 48 (29.45%) | 115 (70.55%) | ||
| Having the option to continue the new treatment after the trial had concluded | 14 (3.01%) | 451 (96.99%) | ||
| Non-underrepresented | 9 (2.97%) | 294 (97.03%) | 0.945 | |
| Underrepresented | 5 (3.09%) | 157 (96.91%) | ||
| The number of visits and total time per month to participate | 81 (17.61%) | 379 (82.39%) | ||
| Non-underrepresented | 56 (18.54%) | 246 (81.46%) | 0.467 | |
| Underrepresented |
25 (15.82%) |
133 (84.18%) |
||
| Health Center System |
Privacy and confidentiality issues | 64 (13.73%) | 402 (86.27%) | |
| Non-underrepresented | 43 (14.19%) | 260 (85.81%) | 0.696 | |
| Underrepresented | 21 (12.88%) | 142 (87.12%) | ||
| The reputation of people or the institution conducting the research | 12 (2.58%) | 454 (97.42%) | ||
| Non-underrepresented | 7 (2.3%) | 298 (97.7%) | 0.599 | |
| Underrepresented |
5 (3.11%) |
156 (96.89%) |
||
| Patient-Physician Relationship |
Keeping my current doctor during the trial | 154 (32.91%) | 314 (67.09%) | |
| Non-underrepresented | 101 (33.01%) | 205 (66.99%) | 0.949 | |
| Underrepresented | 53 (32.72%) | 109 (67.28%) | ||
| My physician's recommendation | 115 (24.63%) | 352 (75.37%) | ||
| Non-underrepresented | 76 (24.92%) | 229 (75.08%) | 0.84 | |
| Underrepresented |
39 (24.07%) |
123 (75.93%) |
||
| Participant | The side effects that might come from being on a new treatment | 40 (8.55%) | 428 (91.45%) | |
| Non-underrepresented | 26 (8.52%) | 279 (91.48%) | 0.981 | |
| Underrepresented | 14 (8.59%) | 149 (91.41%) | ||
| The distance I would have to travel for my trial visits | 45 (9.64%) | 422 (90.36%) | ||
| Non-underrepresented | 28 (9.21%) | 276 (90.79%) | 0.67 | |
| Underrepresented | 17 (10.43%) | 146 (89.57%) | ||
| The potential negative impact the trial could have on my health | 39 (8.37%) | 427 (91.63%) | ||
| Non-underrepresented | 24 (7.92%) | 279 (92.08%) | 0.634 | |
| Underrepresented | 15 (9.2%) | 148 (90.8%) | ||
| An opportunity to possibly improve my own health | 4 (0.85%) | 464 (99.15%) | ||
| Non-underrepresented | 1 (0.33%) | 304 (99.67%) | 0.09 | |
| Underrepresented | 3 (1.84%) | 160 (98.16%) | ||
| The opportunity to improve the health of others | 14 (3%) | 452 (97%) | ||
| Non-underrepresented | 8 (2.62%) | 297 (97.38%) | 0.507 | |
| Underrepresented | 6 (3.73%) | 155 (96.27%) |
1
Frequency (%).
2
Fisher's exact test.